124P A phase I study of percutaneous oncolytic rose bengal disodium for metastatic uveal melanoma patients with hepatic metastases: A single-center cohort summary

ConclusionPercutaneous PV-10 exhibited acceptable safety and tolerability with encouraging evidence of activity in injected lesions. Updated enrollment as well as safety and efficacy data of the uveal melanoma cohort will be presented at the meeting.Clinical trial identificationNCT00986661.Legal entity responsible for the studyProvectus.FundingProvectus.DisclosureS. Patel: Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Cardinal Health; Advisory / Consultancy: Castle Biosciences; Leadership role, Data Safety Monitoring Board Chair: Immunocore; Advisory / Consultancy: Incyte; Honoraria (self): Merck; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Provectus; Leadership role, Research grant / Funding (institution), Data Safety Monitoring Board chair: Reata. E.A. Wachter: Shareholder / Stockholder / Stock options, Full / Part-time employment: Provectus. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research